CAMBRIDGE, Mass.--(BUSINESS WIRE)--Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the appointment of Anna Dixon as senior vice president (SVP), human resources. Ms. Dixon will be responsible for all aspects of Orbital’s human resources operations and strategy, including talent acquisition, talent management and organization development, and will serve as a key member of the executive team.
“Anna's experience designing and implementing strategic, scalable HR programs and initiatives will be invaluable to Orbital during this critical phase of growth to meet the demands of our emerging scientific platform and programs,” said Ron Philip, chief executive officer at Orbital. “I look forward to collaborating with Anna to build and nurture a people-centric culture that fosters innovation, diversity and respect – cornerstones that will drive us toward realizing the full potential of RNA medicines.”
“Orbital has built a strong foundation to support its far-reaching vision of building an expansive portfolio of RNA medicines, and I'm honored to join during such an exciting time,” said Ms. Dixon. “I look forward to partnering across the organization to enhance our talent strategy, drive employee engagement and continue building a dynamic culture as we grow.”
Ms. Dixon brings to Orbital considerable experience in building and leading human resources organizations at life sciences companies. Prior to Orbital, she served as SVP and head of human resources at Pyxis Oncology, where she was responsible for the overall strategic direction of the human resources and talent acquisition functions and served as business partner and contributing member of the senior leadership team. Prior to Pyxis, Ms. Dixon served in roles of increasing responsibility at Solid Biosciences, most recently as VP, human resources. Ms. Dixon earned her master's degree in communication management with a concentration in human resources and employee relations from Emerson College and bachelor’s degree in psychology from the University of Guelph.
About Orbital Therapeutics
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. The company is leveraging its first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics. Founded by experts in the fields of genetic medicine and RNA development and delivery, Orbital has an operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders. For more information, please visit www.OrbitalTx.com.
